Matteo Bauckneht, Associate Professor of Nuclear Medicine at the University of Genoa, shared a post on LinkedIn:
“PSMA-based radioligand therapy is a promising option in the management of metastatic castration-resistant prostate cancer, yet several pitfalls remain in clinical practice.
At EANM25, the session ‘Pitfalls in PSMA-based RLT: case-based review’ will address the most frequent challenges, focusing on practical insights to refine strategies, avoid common errors, and improve patient care.
- LIPS 9 – Oncology and Theranostics Committee
- Tuesday, October 7 | 08:00–09:30
- Save the date – we look forward to seeing you in Barcelona!”
You can find more posts about Prostate Cancer on OncoDaily.